About
Technology
Issues
FAQ
Links
Official Page
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.